FGFR2 and colorectal carcinoma: Next-generation sequencing identified FGFR2 aberrations in a subset (1.4%) of patients with CRC (49) and FGFR2 expression has been seen in 2.9% of patients with CRC (50), indicating some patients may benefit from therapeutic targeting of this protein.